Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Novo Nordisk's modern and new generation insulins
maintain market share in the US insulin market
US fast-acting insulin
Segment volume
US premix insulin
Segment volume
US long-acting insulin
Segment volume
Slide 50
LevemirⓇ share
NovoLogⓇ share
NovoLog® Mix 70/30 share
TresibaⓇ share
tMU
tMU
tMU
CAGR volume¹: 3.2%
80
MI penetration: 83.3%
100%
80
CAGR volume¹: (6.1%)
MI penetration: 52.1%
100%
80
CAGR volume¹: 4.1%
MI penetration: 75.5%
100%
70
70
70
80%
80%
80%
60
60
60
50
- 60%
50
60%
50
60%
40
40
40
40%
30
30
40%
30
40%
20
20
20
20%
20%
20%
10
10
10
0
0%
0%
0
0%
0
Nov
2012
Nov
2017
Nov
2012
Nov
2017
Nov
Nov
2012
2017
1 CAGR for 5-year period; tMU: Thousand mega units
Note: US trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures
changing
diabetes®
novo nordiskView entire presentation